Journals | Policy | Permission

Journal of Clinical Medicine Research

Letter to the Editor

Volume 14, Number 6, June 2022, pages 244-245

The Necessity of Collaboration With Doctors Involved in Annual Medical Checkups in the Identification of Familial Hypercholesterolemia in Japan

Patients with familial hypercholesterolemia (FH), a common genetic disorder, show high blood levels of low-density lipoprotein (LDL) and earlier treatment prevents coronary heart disease; thus, the relevance of the identification of FH to its prevention is emphasized [1]. As the low rate of its diagnosis is an issue in many countries around the world, including Japan [2, 3], systems to identify FH are therefore needed. The primary care settings, as the department of general medicine/practice where patients firstly consult in relation to various health problems, including asymptomatic individuals with abnormal laboratory data, would play an important role in the identification of FH [4]. In the primary care setting, annual medical checkups (community-based mass examination, special health checkups, human dock [5]) also seem to be a potential opportunity to suspect FH.

We surveyed the reasons for the first visit of patients who were consecutively recruited at the general medicine department in our hospital in the years 2015 and 2019, using the International Classification of Primary Care (ICPC) criteria. The ICPC-2 is used internationally to classify chief complaints of patients in the primary care setting [6]. The study was approved by the institutional ethics committee (No. 2020-018). As a result, among the chief complaints of patients on their first visit (n = 3,491 in 2015 and n = 2,640 in 2019), the prevalence of “abnormal laboratory data” was 13.9% (n = 486) in 2015 and 8.6% (n = 223) in 2019, respectively. “Abnormal laboratory data” was the most common chief complaint in both years. Regarding the details of abnormal laboratory data, the prevalence of “dyslipidemias” was 17.7% in 2015 and 40.5% in 2019, respectively (Table 1). Among the types of dyslipidemias, the prevalence of LDL-cholesterol levels of ≥ 180 mg/dL [1] was 23.3% in 2015 and 41.3% in 2019. The prevalence of LDL-cholesterol levels of ≥ 200 mg/dL was 7.0% in 2015 and 15.2% in 2019. Almost all the patients were introduced to our hospital by doctors involved in annual medical checkups, where FH was not strongly suggested in such cases at the time of introduction. We could consider FH based on the clinical background and administered statins in cases (three cases in 2015 and 11 cases in 2019) with LDL-cholesterol levels of ≥ 180 mg/dL.

Click to view

Table 1. The Prevalence of Dyslipidemias as the Reason for the First Visit for “Abnormal Laboratory Data”

In Japan, annual medical checkups are popularly conducted and can be a possible chance to identify FH from our survey. However, when FH is asymptomatic and/or at a relatively early stage as well as FH is not suggested in the checkups, the patients may not visit hospitals. Since Japan’s medical care system has specific features, such as free access to doctors at the first visit, not only general practitioners but also specialists (i.e., ophthalmologists, dermatologists, plastic surgeons, orthopedic surgeons, etc.) are required to be enlightened about the identification of FH [4]. Systems of consultation, in which general practitioners and specialists with little experience and knowledge in FH-related areas can collaborate with specialists in FH, are also necessary [4]. Additionally, from our survey, collaboration with doctors involved in annual medical checkups should be reinforced, for instance by more education on FH and feedback on the diagnosis of FH to such doctors.

Acknowledgments

None to declare.

Financial Disclosure

This work was supported in part by Scientific Research from the Foundation for Development of Community.

Conflict of Interest

None to declare.

Informed Consent

The study was approved in an opt-out consent manner.

Author Contributions

KK designed the study. EK and KK wrote the article. EK prepared data. All authors approved the manuscript for submission.

Data Availability

The data of this study are available on request from the corresponding author depending on the conditions.

1. Harada-Shiba M, Arai H, Ishigaki Y, Ishibashi S, Okamura T, Ogura M, Dobashi K, et al. Guidelines for diagnosis and treatment of familial hypercholesterolemia 2017. J Atheroscler Thromb. 2018;25(8):751-770.
   doi pubmed
2. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478-3490a.
3. EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet. 2021;398(10312):1713-1725.
4. Kotani K. Primary care systems with interprofessional collaboration in the diagnosis and management of familial hypercholesterolaemia. Aust J Gen Pract. 2022;51:e1.
5. Yamashita T, Funatsu K, Kondo S, Yokoyama M, Mizuno K, Nakamura H. [From the point of view of health evaluation and promotion (Ningen Dock) facilities]. Rinsho Byori. 2014;62(9):892-894.
6. World Organization of Family Doctors (WONCA). ICPC-2, International classification of primary care. 2nd edition. Oxford: Oxford University Press. 1997.

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Journal of Clinical Medicine Research is published by Elmer Press Inc.